Ally Bridge joins Bain in $120M bet that speeding up manufacturing QC can hit big in post-pandemic world
The global tide of venture and private equity money flooding into biopharma — undeterred, if not boosted, by the public health crisis — is floating the boats of not just drug developers but also the vendors that help them do their job. In the latest example, China’s Ally Bridge Group and Switzerland’s Endeavour Vision have joined Bain Capital in contributing to Rapid Micro Biosystems’ $120 million financing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.